-

DNOW Alert: Hagens Berman Reminds DNOW Inc. (DNOW) Investors of Approaching Lead Plaintiff Deadline in Securities Class Action

SAN FRANCISCO--(BUSINESS WIRE)--Hagens Berman urges investors in DNOW Inc. (NYSE: DNOW) who suffered significant losses to contact the firm regarding the pending securities class action.

“We are focused on whether the Proxy Materials downplayed ERP integration failures at MRC Global allowing management to push the deal through, as the complaint alleges,” said Reed Kathrein, Hagens Berman partner.

Share
  • Lead Plaintiff Deadline: Oct. 2, 2026
  • Class Eligibility: Shareholders holding DNOW common stock as of the August 5, 2025 record date entitled to vote at DNOW’s September 9, 2025 special meeting on the merger with MRC Global

Visit: www.hbsslaw.com/dnow or contact Partner Reed Kathrein at 844-776-6152 or DNOW@hbsslaw.com.

Blog: www.hbsslaw.com/blog/dnow-the-synergy-charade

Case Allegations:

The lawsuit alleges that DNOW’s Proxy Materials issued in connection with its acquisition of MRC Global Inc. contained materially false and misleading statements and omitted critical operational risks.

Specifically, Proxy Materials allegedly failed to disclose:

  • Severe operational integration challenges stemming from critical defects in MRC Global’s newly implemented Enterprise Resource Planning (ERP) software system.
  • Material disruption to inventory tracking, order fulfillment, and financial forecasting prior to the merger approval.
  • Artificially inflated valuation assumptions for the combined entity presented to voting shareholders.

When the truth regarding the ERP software implementation failures and reduced financial guidance was revealed, DNOW stock plummeted.

What Affected DNOW Shareholders Can Do

Shareholders who were eligible to vote on the merger and suffered financial losses have until October 2, 2026 to petition the Court to serve as Lead Plaintiff. A Lead Plaintiff represents the broader class in directing litigation strategy. Click here to learn more about options to recover losses.

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contacts

Hagens Berman, Reed Kathrein, 715 Hearst Avenue, Suite 300, Berkeley, CA 94710, 844-916-0895, DNOW@hbsslaw.com

Hagens Berman

NYSE:DNOW

Release Summary
Hagens Berman is investigating claims in a class action complaint filed on behalf of investors in DNOW Inc. (DNOW) against the Company.
Release Versions
$Cashtags

Contacts

Hagens Berman, Reed Kathrein, 715 Hearst Avenue, Suite 300, Berkeley, CA 94710, 844-916-0895, DNOW@hbsslaw.com

Social Media Profiles
More News From Hagens Berman

Webull (BULL) Faces Securities Class Action Amid House Committee Findings: “Profound Gap” Between Company Statements and Operational Reality – HBSS

SAN FRANCISCO--(BUSINESS WIRE)--Hagens Berman is investigating claims in a class action complaint filed on behalf of investors in Webull Corporation (BULL) against the Company....

CORRECTING and REPLACING University of Washington Sorority Member Represented by Hagens Berman Sues UW Following Pi Kappa Phi Fraternity Sexual Assault

SEATTLE--(BUSINESS WIRE)--Attorneys at Hagens Berman represent a survivor of a sexual assault that occurred at University of Washington’s Pi Kappa Phi fraternity in Seattle....

Trial Lawyer Who Bested Big Tobacco Turns 45 Years of Courtroom Battles into Legal Thriller, Poison in the System

SEATTLE--(BUSINESS WIRE)--Steve Berman, managing partner and co-founding attorney of Hagens Berman has turned his 45-year career into a legal thriller, Poison in the System....
Back to Newsroom